Broadcast Date: 
  • Time: 

Genome editing technologies have taken hold of the life science industry, giving rise to novel life-saving therapies not previously thought possible. The number of investigational new drug filings for cell and genome editing therapies has boomed over the last few years, facilitated in large part by the efficiency and simplicity of the CRISPR system. CRISPR’s swift transition from research tool to therapeutic agent is unprecedented in translational medicine, making it one of the most important and exciting scientific breakthroughs in recent decades. In this GEN webinar, our presenters discuss what it will take to make CRISPR reagents suitable for use in human therapies, as these technologies move from the bench to the clinic.

A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.

Produced with support from:

synthego logo
Aldevron logo
Mark DeWitt, PhD

Mark DeWitt, PhD
Project Scientist

Thomas Foti
Protein Business Unit

Robert Deans, PhD
Chief Scientific Officer